These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 24415642)

  • 1. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
    Santoni M; Conti A; Massari F; Arnaldi G; Iacovelli R; Rizzo M; De Giorgi U; Trementino L; Procopio G; Tortora G; Cascinu S
    Int J Cancer; 2015 Jan; 136(1):1-10. PubMed ID: 24415642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
    Santoni M; Conti A; De Giorgi U; Iacovelli R; Pantano F; Burattini L; Muzzonigro G; Berardi R; Santini D; Cascinu S
    Int J Cancer; 2014 Aug; 135(4):763-73. PubMed ID: 24127298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
    Shantakumar S; Nordstrom BL; Djousse L; Hall SA; Gagnon DR; Fraeman KH; van Herk-Sukel M; Chagin K; Nelson J
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):559-66. PubMed ID: 27438066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
    Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
    J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
    Sikic D; Lüdecke G; Lieb V; Keck B
    Urologe A; 2016 May; 55(5):648-52. PubMed ID: 27119958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
    Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
    Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
    Alasker A; Meskawi M; Sun M; Ismail S; Hanna N; Hansen J; Tian Z; Bianchi M; Perrotte P; Karakiewicz PI
    Cancer Treat Rev; 2013 Jun; 39(4):388-401. PubMed ID: 23317510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
    Qi WX; Lin F; Sun YJ; Tang LN; He AN; Yao Y; Shen Z
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):431-9. PubMed ID: 23178953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pazopanib outscores sunitinib on tolerability.
    Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
    Motzer RJ; Hutson TE; Cella D; Reeves J; Hawkins R; Guo J; Nathan P; Staehler M; de Souza P; Merchan JR; Boleti E; Fife K; Jin J; Jones R; Uemura H; De Giorgi U; Harmenberg U; Wang J; Sternberg CN; Deen K; McCann L; Hackshaw MD; Crescenzo R; Pandite LN; Choueiri TK
    N Engl J Med; 2013 Aug; 369(8):722-31. PubMed ID: 23964934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
    Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience.
    Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu GK; Lokanatha D; Jacob LA; Suresh Babu MC; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(4):626-630. PubMed ID: 30082547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
    Leung HW; Chan AL
    Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?].
    Joly F
    Bull Cancer; 2011 Oct; 98(9):1071-81. PubMed ID: 21914577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of pazopanib over sunitinib for renal cell carcinoma.
    Granovetter M
    Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
    Jang S; Zheng C; Tsai HT; Fu AZ; Barac A; Atkins MB; Freedman AN; Minasian L; Potosky AL
    Cancer; 2016 Jan; 122(1):124-30. PubMed ID: 26439451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].
    Keil C; Götze L; Olbert P; Hofmann R; Nockher WA; Hegele A
    Urologe A; 2015 Jun; 54(6):811-8. PubMed ID: 25503897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
    Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.